Webinar
2022 NRDL Pricing Implications and Access Outcomes
Available On Demand
What are the latest pricing dynamics from the 2022 NRDL update that manufacturers should learn to succeed in China market access?
The 2022 National Reimbursement Drug List (NRDL) negotiation has recently published the list of successfully negotiated drugs and their post-negotiation prices. The results indicate an improved access environment for new and high-cost innovative therapies.
In this webinar, Trinity Life Sciences’ Value, Access and Pricing experts will provide an in-depth analysis of the 2022 NRDL and key trends from previous NRDL negotiations. We will discuss the pricing implications and evidence strategies needed to secure public funding in China, along with how to navigate key NRDL strategies.
Key Webinar Topics:
- Introduction to NRDL and China access landscape overview
- Key updates in 2022 NRDL
- Case studies of oncology, rare disease and chronic disease drugs
